Publications | Flatiron Health | Hematologic malignancies

Browse every publication tagged Hematologic malignancies

October 2026
Curation of clinically enriched real-world data for multiple myeloma research in Japan
April 2026
Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens
- Hematologic malignancies
- Treatment and Testing patterns
April 2026
Evaluating model performance for between-country survival transportability
- Methodology
- Hematologic malignancies
March 2026
Health disparities in acute myeloid leukemia patients undergoing treatment with tyrosine kinase inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2
December 2025
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies
- Regulatory
- Hematologic malignancies
November 2025
Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma
- Hematologic malignancies
- Treatment and Testing patterns
November 2025
Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany
- Hematologic malignancies
November 2025
What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma
- Hematologic malignancies
November 2025
The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access
- Hematologic malignancies